Evotec SE (EVO): Financial results for H2 2026

Evotec SE (EVO) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 For further information, please contact : Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 9M 2026 HIGHLIGHTS 4 D&PD LEADING COMMERCIAL INDICATORS SHOW CONTIN

Event · Earnings
Also in this documentGuidance · reaffirm · €570–€610

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 5, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$EVO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

Med
01

Why it matters

The interim results show a material revenue decline but cost cuts and a savings program, with guidance unchanged, likely prompting a sell‑off.

02

Market read

Earnings miss with reaffirmed guidance may drive short‑term downside for Evotec and related European biotech stocks.

03

What to watch

Cost reductions and Horizon savings program could improve margins later in the year.

Relevance 7/10Novelty 8/10Timing: after-hours release
AlphAI · Earnings readEVO · 9M 2026 · ended September 30, 2026

NINE-MONTH 2026 RESULTS ABOVE MARKET EXPECTATIONS; FULL-YEAR 2026 GUIDANCE REAFFIRMED

→Mixed quarter

Revenue, gross margin, adjusted Group EBITDA, net loss and operating cash flow deteriorated year over year, while Evotec reaffirmed its full-year 2026 revenue and adjusted Group EBITDA guidance and reported Horizon slightly ahead of schedule.

Revenue
€465M
decreased by 13.1% y/y
Discovery & Preclinical Development (D&PD), 9M 2026
€348M
declined by 11.2% y/y
Gross margin · other
3.6%
EPS · other
(1.10)
Full-year 2026 outlook
€ 570 – 610 m (€ 595 – 635 m CER; 2025: € 788.4 m)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Group revenue, 9M 2026other€465M–decreased by 13.1%
Group revenue at constant exchange rates, 9M 2026other€477.4M–declined by 10.8%
Base revenue, 9M 2026other€441.1M–decreased by 12.4%
Cost of revenue, 9M 2026other€448.4M––
Gross profit, 9M 2026other€16.65M––
Group gross margin, 9M 2026other3.6%––
Research and development costs, 9M 2026other€29.7M–decreased by 29.8%
Selling, general and administrative expenses, 9M 2026other€121.9M–€ 16.5 m or 11.9% lower
Other operating income, 9M 2026other€31.2M––
Other operating expenses, 9M 2026other€59.1M––
Reorganization costs, 9M 2026other€91.9M––
Operating loss, 9M 2026other€254.8M––
Adjusted Group EBITDA, 9M 2026non-GAAP−€44.3M––
Net loss, 9M 2026other€195.3M––
Net result per share, basic, 9M 2026other(1.10)––
Net result per share, diluted, 9M 2026other(1.10)––
Average employees, 9M 2026other4,379 people–decrease of 378 (7.9%)

Segments

SegmentRevenueq/qy/y
Discovery & Preclinical Development (D&PD), 9M 2026The decrease was primarily driven by lower sales-to-revenue conversion across all D&PD business areas, reflecting ongoing timing effects in commercial activities despite early signs of improvement in the market.€348.2M–declined by 11.2%
Just – Evotec Biologics (JEB), 9M 2026The decline was primarily driven by the USD 25 m Sandoz license sale recognized in Q1 2025 and delayed program activities.€117.1M–decreased by 18.3%

Full-year 2026 outlook

  • Revenue€ 570 – 610 m (€ 595 – 635 m CER; 2025: € 788.4 m)
  • NoteAdjusted Group EBITDA is expected to reach € (70) – (105) m (€ (60) – (90) m CER; 2025: € 41.1 m).

What drove it

  • D&PD revenue was affected by lower sales-to-revenue conversion across all business areas and timing effects in commercial activities.
  • JEB revenue was affected by the USD 25 m Sandoz license sale recognized in Q1 2025, delayed program activities and customer project progression.
  • D&PD gross margin was affected by lower top-line performance and continued underutilization.
  • JEB gross margin reflected delayed program activities, temporarily higher material and project costs due to production phasing, and the Sandoz license income in Q1 2025.
  • R&D expenses declined through more focused capital allocation to selected R&D projects.
  • D&PD SG&A declined mainly due to lower personnel costs following Horizon and reduced consultancy expenses.
  • Horizon is progressing slightly ahead of schedule and supports the plan to realize 20–30% of the € 75 m run-rate savings from 2027 into 2026.

Concerns

  • Group gross margin fell to 3.6% from 10.7%, including a JEB gross margin of (9.5)% compared with 2.7%.
  • Adjusted Group EBITDA loss widened to € (44.3) m from € (16.9) m.
  • Reorganization costs were € 91.9 m, including € 43.3 m attributable to personnel measures and € 43.1 m of impairment losses on property, plant and equipment at affected sites.
  • Other operating expenses included an impairment loss of € 42.3 m relating to a laboratory building in Hamburg.
  • Net cash used in operating activities was € (155.0) m, compared with € (72.8) m.
  • Total Liquidity decreased to € 400.9 m from € 476.4 m, while Current and Non-current financial liabilities increased to € 481.8 m from € 448.7 m.

What to watch

  • Sales-to-revenue conversion and timing effects across D&PD business areas.
  • JEB customer project progression, program-related activities, production phasing and material costs.
  • Delivery of Horizon measures and realization of 20–30% of the € 75 m run-rate savings from 2027 into 2026.
  • The full-year 2026 revenue range of € 570 – 610 m and adjusted Group EBITDA range of € (70) – (105) m.
  • Operating cash flow, liquidity and financial liabilities following nine-month operating cash use of € (155.0) m.

Balance sheet and cash flow

  • Net cash provided by (used in) operating activities, 9M 2026: € (155.0) m (9M 2025: € (72.8) m).
  • Net cash provided by (used in) investing activities, 9M 2026: € 14.8 m (9M 2025: € (50.8) m).
  • Capital expenditure, 9M 2026: € (19.2) m (9M 2025: € (57.8) m).
  • Proceeds from the disposal of Tubulis GmbH, net of hedging: € 87.8 m.
  • Net cash provided by (used in) financing activities, 9M 2026: € 23.0 m (9M 2025: € 8.6 m).
  • Cash and cash equivalents as of September 30, 2026: € 299,012 k (December 31, 2025: € 418,517 k).
  • Total Liquidity (Cash and cash equivalents and Current investments): € 400.9 m (December 31, 2025: € 476.4 m).
  • Current and Non-current financial liabilities: € 481.8 m (December 31, 2025: € 448.7 m).
  • Total assets: € 1,505.0 m (December 31, 2025: € 1,713.9 m).
  • Total liabilities: € 863.3 m (December 31, 2025: € 900.2 m).
  • Total stockholders’ equity: € 641.7 m (December 31, 2025: € 813.7 m).
  • Equity ratio as of September 30, 2026: 42.6% (December 31, 2025: 47.5%).

Analysis

Evotec reported nine-month revenue of € 465.0 m, down 13.1% from € 535.1 m, with base revenue decreasing 12.4% to € 441.1 m. At constant exchange rates, Group revenue declined 10.8% to € 477.4 m. D&PD revenue declined 11.2% to € 348.2 m as lower sales-to-revenue conversion and commercial timing effects affected all business areas. JEB revenue decreased 18.3% to € 117.1 m, reflecting the USD 25 m Sandoz license sale recognized in Q1 2025 and delayed program activities.

Profitability weakened materially. Group gross margin fell to 3.6% from 10.7%, with D&PD margin decreasing to 8.0% from 13.6% and JEB margin falling to (9.5)% from 2.7%. Lower revenue and underutilization pressured D&PD, while JEB absorbed delayed program activity and temporarily higher material and project costs from production phasing. Adjusted Group EBITDA was a loss of € (44.3) m, compared with a loss of € (16.9) m, despite lower R&D and SG&A expenses.

The reported net loss widened to € 195.3 m from € 118.1 m. The period included € 91.9 m of Horizon-related reorganization costs and an impairment loss of € 42.3 m relating to a Hamburg laboratory building. Horizon-related costs included € 43.3 m for personnel measures and € 43.1 m of property, plant and equipment impairment losses at affected sites. Management stated that Horizon is progressing slightly ahead of schedule and remains positioned to bring 20–30% of the € 75 m run-rate savings planned for 2027 into 2026.

Cash generation and liquidity remain key points of attention. Operating cash flow was € (155.0) m, versus € (72.8) m in 9M 2025. Investing cash flow was positive at € 14.8 m, supported by proceeds from the Tubulis GmbH disposal, while financing cash flow was € 23.0 m, driven by convertible bonds and other loans partly offset by debt and lease repayments. Total Liquidity declined to € 400.9 m and Current and Non-current financial liabilities increased to € 481.8 m.

Evotec reaffirmed full-year 2026 guidance for Group revenues of € 570 – 610 m and adjusted Group EBITDA of € (70) – (105) m. The filing characterizes nine-month revenue and adjusted EBITDA as consistent with the full-year guidance ranges. The principal execution markers for the remainder of the year are D&PD sales conversion, JEB program timing and project progression, realization of Horizon savings, and the trajectory of operating cash use.

Not in the filing

stated, not guessed
  • Standalone Q3 2026 financial statements and standalone Q3 2025 comparisons were not provided.
  • Prior-quarter comparisons for reported nine-month metrics were not provided.
  • Free cash flow was not reported.
  • Dividend payments, share repurchases and other capital-return programs were not reported.
  • A separate debt figure was not reported; the filing reports Current and Non-current financial liabilities.
  • Forward guidance for gross margin, operating expenses and tax rate was not provided.
  • Named executive earnings commentary and attributable executive quotes were not provided.
  • The accounting framework was not specified in the provided filing text.
  • The previous outlook covered the full year 2026, and this release reports the nine months to September 30, 2026, so there is no matching guidance to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Evotec SE is a German drug discovery and development company that files Form 6‑K for earnings disclosures.

Market effects

Biotech and drug discovery sector may see broader scrutiny as Evotec's revenue decline signals market softness.

European biotech stocks could face short‑term pressure.

Limited, primarily affecting Evotec and peers in the European life‑sciences space.

Counterpoint

The reaffirmed guidance may be a floor, and any upside could come from upcoming AI‑enabled collaborations.

Key entities

  • Evotec SE

    German biotech firm reporting H2 2026 results.

Every EVO earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$EVOMedAI 8/10

Evotec secures second FDA clearance under BMS partnership

Evotec SE said the FDA accepted a second IND for a CELMoD molecular glue degrader under its partnership with Bristol Myers Squibb. Evotec expects Phase 1 in 2027, after the first candidate entered Phase 1 in March 2026 for advanced clear cell renal cell carcinoma.

$EVOMedAI 8/10

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

Evotec (EVO) and Bristol Myers Squibb received FDA clearance for a second Investigational New Drug (IND) in their protein degradation partnership. The first candidate entered Phase 1 trials in March 2026, and the second is expected to start in 2027. The collaboration leverages Evotec's drug discovery capabilities and Bristol Myers Squibb's CELMoD agent library to develop molecular glue degraders for oncology and other therapeutic areas.

$EVOMed

What Evotec (EVO) Said on Its Q3 Earnings Call

Evotec (EVO) expects Q4 revenue and profitability to decline due to lower milestone contributions. Net sales in D&PD base business rose 24% YoY in the first nine months. The company plans a manufacturing expansion in 2027 and has achieved 20% of its €75M annual savings target. Evotec reiterated its 2030 revenue goal of €1B and a 20% EBITDA margin by 2030.